Status:
COMPLETED
Effects of Angiotensin Converting Enzyme (ACE) Inhibitors Versus Candesartan in Reducing Cardiovascular Events in Primary Treatment of Hypertension
Lead Sponsor:
AstraZeneca
Conditions:
Hypertension
Cardiovascular Disease
Eligibility:
All Genders
17+ years
Brief Summary
The planned Study will be a retrospective study on the effect of ACE's vs. candesartan on cardiovascular events and on health economic effects in a "real life" setting in Sweden.
Eligibility Criteria
Inclusion
- all patients found in electronic patient journals at the participating centres, who were prescribed either ACEis (ATC-C09A-B) or ARBs (C09C-D) for hypertension from 1 January 1999 - 31 December 2007. The first date of such a prescription starts the observation time and is called the index prescription.
Exclusion
- No history of cardiovascular disease.
- Ongoing malignancy
Key Trial Info
Start Date :
June 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2010
Estimated Enrollment :
50000 Patients enrolled
Trial Details
Trial ID
NCT01152567
Start Date
June 1 2010
End Date
November 1 2010
Last Update
September 27 2011
Active Locations (56)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Avesta, Sweden
2
Research Site
Älvdalen, Sweden
3
Research Site
Ängelholm, Sweden
4
Research Site
Åkersberga, Sweden